Browsing: pharmaceutical industry

Even before the COVID-19 epidemic hit, FDA inspections of drug manufacturing facilities – especially those located outside the United States, including India and China – were lax at best. The main problem? Too many facilities to inspect and not enough inspectors.

This article was originally published on STAT on December 18, 2018. How would you feel if you were harmed by…

As someone who has high cholesterol — including high triglycerides — and who also takes a statin medication, a news…

Many FDA advisory committee members later receive kickbacks from the very pharma companies whose drug they approved. How can we…

The FDA has issued new guidance for drug companies in an effort to provide better information on the “indications and…

While many drugs are being approved more rapidly, are they much of an improvement over existing medications? What are the…

A stroll around the exhibit area of the American Psychiatric Association Conference demonstrates how pharma marketing can influence the prescribing…

The leukemia drug Mylotarg (gemtuzumab ozogamicin), which was voluntarily withdrawn from the market in 2010 over safety concerns and questions…

Would allowing pharmaceutical companies to include fewer risks in television and print ads be good for consumers? Members of the…

Criticism that the FDA doesn’t approve drugs fast enough ignores the fact that most drugs are approved in the US…